TY - JOUR
T1 - Allergic reactions to current available covid-19 vaccinations
T2 - Pathophysiology, causality, and therapeutic considerations
AU - Kounis, Nicholas G.
AU - Koniari, Ioanna
AU - de Gregorio, Cesare
AU - Velissaris, Dimitris
AU - Petalas, Konstantinos
AU - Brinia, Aikaterini
AU - Assimakopoulos, Stelios F.
AU - Gogos, Christos
AU - Kouni, Sophia N.
AU - Kounis, George N.
AU - Calogiuri, Gianfranco
AU - Hung, Ming Yow
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Vaccines constitute the most effective medications in public health as they control and prevent the spread of infectious diseases and reduce mortality. Similar to other medications, allergic reactions can occur during vaccination.While most reactions are neither frequent nor serious, ana-phylactic reactions are potentially life-threatening allergic reactionsthat are encountered rarely, but can cause serious complications.The allergic responses caused by vaccines can stem fromactivation of mast cells via Fcε receptor-1 type I reaction, mediated by the interaction between immunoglobulin E (IgE) antibodies against a particular vaccine, and occur within minutes or up to four hours. The type IV allergic reactions initiate 48 h after vaccination and demonstrate their peak between 72 and 96 h. Non-IgE-mediated mast cell degranulation via activation of the complement system and via activation of the Mas-related G protein-coupled receptor X2 can also induce allergic reactions. Reactions are more often caused by inert substances, called excipients, which are added to vaccines to improve stability and absorption, increase solubility, influence palatability, or create a distinctive appearance, and not by the active vaccine itself. Polyethylene glycol, also known as macrogol, in the currently available Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines, and polysorbate 80, also known as Tween 80, in AstraZeneca and Johnson & Johnson COVID-19 vaccines, are excipients mostly incriminated for allergic reactions. This review will summarize the current state of knowledge of immediate and delayed allergic reactions in the currently available vaccines against COVID-19, together with the general and specific therapeutic considerations. These considerations include:The incidence of allergic reactions and deaths under investigation with the available vaccines, application of vaccination in patients with mast cell disease, patients who developed an allergy during the first dose, vasovagal symptoms masquerading as allergic reactions, the COVID-19 vaccination in pregnancy, deaths associated with COVID-19 vaccination, and questions arising in managing of this current ordeal.Careful vaccine-safety surveillance over time, in conjunction with the elucidation of mechanisms of adverse events across different COVID-19 vaccine platforms, will contribute to the development of a safe vaccine strategy.Allergists’ expertise in proper diagnosis and treatment of allergic reactions is vital for thescreening of high-risk individuals.
AB - Vaccines constitute the most effective medications in public health as they control and prevent the spread of infectious diseases and reduce mortality. Similar to other medications, allergic reactions can occur during vaccination.While most reactions are neither frequent nor serious, ana-phylactic reactions are potentially life-threatening allergic reactionsthat are encountered rarely, but can cause serious complications.The allergic responses caused by vaccines can stem fromactivation of mast cells via Fcε receptor-1 type I reaction, mediated by the interaction between immunoglobulin E (IgE) antibodies against a particular vaccine, and occur within minutes or up to four hours. The type IV allergic reactions initiate 48 h after vaccination and demonstrate their peak between 72 and 96 h. Non-IgE-mediated mast cell degranulation via activation of the complement system and via activation of the Mas-related G protein-coupled receptor X2 can also induce allergic reactions. Reactions are more often caused by inert substances, called excipients, which are added to vaccines to improve stability and absorption, increase solubility, influence palatability, or create a distinctive appearance, and not by the active vaccine itself. Polyethylene glycol, also known as macrogol, in the currently available Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines, and polysorbate 80, also known as Tween 80, in AstraZeneca and Johnson & Johnson COVID-19 vaccines, are excipients mostly incriminated for allergic reactions. This review will summarize the current state of knowledge of immediate and delayed allergic reactions in the currently available vaccines against COVID-19, together with the general and specific therapeutic considerations. These considerations include:The incidence of allergic reactions and deaths under investigation with the available vaccines, application of vaccination in patients with mast cell disease, patients who developed an allergy during the first dose, vasovagal symptoms masquerading as allergic reactions, the COVID-19 vaccination in pregnancy, deaths associated with COVID-19 vaccination, and questions arising in managing of this current ordeal.Careful vaccine-safety surveillance over time, in conjunction with the elucidation of mechanisms of adverse events across different COVID-19 vaccine platforms, will contribute to the development of a safe vaccine strategy.Allergists’ expertise in proper diagnosis and treatment of allergic reactions is vital for thescreening of high-risk individuals.
KW - Allergy
KW - Anaphylaxis
KW - COVID-19
KW - Kounis syndrome
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85102693270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102693270&partnerID=8YFLogxK
U2 - 10.3390/vaccines9030221
DO - 10.3390/vaccines9030221
M3 - Review article
AN - SCOPUS:85102693270
SN - 2076-393X
VL - 9
SP - 1
EP - 19
JO - Vaccines
JF - Vaccines
IS - 3
M1 - 221
ER -